Holmström, M O
Riley, C H
Svane, I M
Hasselbalch, H C
Andersen, M H
Article History
First Online: 18 August 2016
Competing interests
: No authors have conflicts of interest to disclose. However, it should be noted that Morten Orebo Holmström, Hans Carl Hasselbalch and Mads Hald Andersen have filed a patent regarding the <i>CALR</i> exon 9 mutations as a target for cancer immune therapy. The patent has been transferred to University Hospital Zealand, Zealand Region and Copenhagen University Hospital at Herlev, Capital Region according to the Danish Law concerning inventions made at public research institutions.